{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:51:18Z","timestamp":1781092278176,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21440"],"award-info":[{"award-number":["21440"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC#22\/2018"],"award-info":[{"award-number":["FFC#22\/2018"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>High-mobility group box 1 protein (HMGB1) is an ubiquitous nuclear protein that once released in the extracellular space acts as a Damage Associated Molecular Pattern and promotes inflammation. HMGB1 is significantly elevated during <jats:italic>Pseudomonas aeruginosa<\/jats:italic> infections and has a clinical relevance in respiratory diseases such as Cystic Fibrosis (CF). Salicylates are HMGB1 inhibitors. To address pharmacological inhibition of HMGB1 with small molecules, we explored the therapeutic potential of pamoic acid (PAM), a salicylate with limited ability to cross epithelial barriers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PAM binding to HMGB1 and CXCL12 was tested by Nuclear Magnetic Resonance Spectroscopy using chemical shift perturbation methods, and inhibition of HMGB1\u00b7CXCL12-dependent chemotaxis was investigated by cell migration experiments. Aerosol delivery of PAM, with single or repeated administrations, was tested in murine models of acute and chronic <jats:italic>P. aeruginosa<\/jats:italic> pulmonary infection in C57Bl\/6NCrlBR mice. PAM efficacy was evaluated by read-outs including weight loss, bacterial load and inflammatory response in lung and bronco-alveolar lavage fluid.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our data and three-dimensional models show that PAM is a direct ligand of both HMGB1 and CXCL12. We also showed that PAM is able to interfere with heterocomplex formation and the related chemotaxis in vitro. Importantly, PAM treatment by aerosol was effective in reducing acute and chronic airway murine inflammation and damage induced by <jats:italic>P. aeruginosa<\/jats:italic>. The results indicated that PAM reduces leukocyte recruitment in the airways, in particular neutrophils, suggesting an impaired in vivo chemotaxis. This was associated with decreased myeloperoxidase and neutrophil elastase levels. Modestly increased bacterial burdens were recorded with single administration of PAM in acute infection; however, repeated administration in chronic infection did not affect bacterial burdens, indicating that the interference of PAM with the immune system has a limited risk of pulmonary exacerbation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This work established the efficacy of treating inflammation in chronic respiratory diseases, including bacterial infections, by topical delivery in the lung of PAM, an inhibitor of HMGB1.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10020-022-00535-z","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T09:02:52Z","timestamp":1662541372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pamoic acid is an inhibitor of HMGB1\u00b7CXCL12 elicited chemotaxis and reduces inflammation in murine models of Pseudomonas aeruginosa pneumonia"],"prefix":"10.1186","volume":"28","author":[{"given":"Federica","family":"De Leo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Marchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cigana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medede","family":"Melessike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Quilici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"De Fino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malisa Vittoria","family":"Mantonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bragonzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Emilio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0469-2994","authenticated-orcid":false,"given":"Giovanna","family":"Musco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"issue":"1","key":"535_CR1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s10020-020-00172-4","volume":"26","author":"U Andersson","year":"2020","unstructured":"Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med. 2020;26(1):42.","journal-title":"Mol Med"},{"key":"535_CR2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12601","volume":"280","author":"ME Bianchi","year":"2017","unstructured":"Bianchi ME, Crippa MP, Manfredi AA, Mezzapelle R, Rovere Querini P, Venereau E. High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. Immunol Rev. 2017;280:74\u201382.","journal-title":"Immunol Rev"},{"issue":"8","key":"535_CR3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ijmm.2010.08.012","volume":"300","author":"A Bragonzi","year":"2010","unstructured":"Bragonzi A. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int J Med Microbiol. 2010;300(8):584\u201393.","journal-title":"Int J Med Microbiol"},{"issue":"2","key":"535_CR4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1164\/rccm.200812-1943OC","volume":"180","author":"A Bragonzi","year":"2009","unstructured":"Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari S, Rejman J, et al. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med. 2009;180(2):138\u201345.","journal-title":"Am J Respir Crit Care Med"},{"key":"535_CR5","doi-asserted-by":"crossref","first-page":"368.e1\u20139","DOI":"10.1016\/j.cmi.2014.11.004","volume":"21","author":"V Chirico","year":"2015","unstructured":"Chirico V, Lacquaniti A, Leonardi S, Grasso L, Rotolo N, Romano C, et al. Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: High-mobility group box 1 (HMGB1) between inflammation and infection. Clin Microbiol Infect. 2015;21:368.e1-9.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"535_CR6","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2119\/molmed.2015.00148","volume":"21","author":"HW Choi","year":"2015","unstructured":"Choi HW, Tian M, Song F, Venereau E, Preti A, Park S-W, et al. Aspirin\u2019s active metabolite salicylic acid targets high mobility group box 1 to modulate inflammatory responses. Mol Med. 2015;21(1):526\u201335.","journal-title":"Mol Med"},{"key":"535_CR7","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1517\/14656566.2012.686169","volume":"13","author":"P Chue","year":"2012","unstructured":"Chue P, Chue J. A review of olanzapine pamoate. Expert Opin Pharmacother. 2012;13:1661\u201370.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"535_CR8","doi-asserted-by":"crossref","first-page":"21465","DOI":"10.1038\/srep21465","volume":"6","author":"C Cigana","year":"2016","unstructured":"Cigana C, Lor\u00e8 NI, Riva C, De Fino I, Spagnuolo L, Sipione B, et al. Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections. Sci Rep. 2016;6(1):21465.","journal-title":"Sci Rep"},{"issue":"3","key":"535_CR9","doi-asserted-by":"crossref","first-page":"1802456","DOI":"10.1183\/13993003.02456-2018","volume":"55","author":"C Cigana","year":"2020","unstructured":"Cigana C, Ranucci S, Rossi A, De Fino I, Melessike M, Bragonzi A. Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa. Eur Respir J. 2020;55(3):1802456.","journal-title":"Eur Respir J"},{"key":"535_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.00001","volume":"9","author":"G D\u2019Agostino","year":"2018","unstructured":"D\u2019Agostino G, Cecchinato V, Uguccioni M. Chemokine heterocomplexes and cancer: a novel chapter to be written in tumor immunity. Front Immunol. 2018;9:1\u20138.","journal-title":"Front Immunol"},{"issue":"10","key":"535_CR11","doi-asserted-by":"crossref","first-page":"e47788","DOI":"10.15252\/embr.201947788","volume":"20","author":"F De Leo","year":"2019","unstructured":"De Leo F, Quilici G, Tirone M, De Marchis F, Mannella V, Zucchelli C, et al. Diflunisal targets the HMGB1\/CXCL12 heterocomplex and blocks immune cell recruitment. EMBO Rep. 2019;20(10):e47788.","journal-title":"EMBO Rep"},{"key":"535_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fchem.2020.598710","volume":"8","author":"F De Leo","year":"2020","unstructured":"De Leo F, Quilici G, De Marchis F, Mantonico MV, Bianchi ME, Musco G. Discovery of 5,5\u2032-methylenedi-2,3-cresotic acid as a potent inhibitor of the chemotactic activity of the HMGB1\u00b7CXCL12 heterocomplex using virtual screening and NMR validation. Front Chem. 2020;8:1\u201317.","journal-title":"Front Chem"},{"issue":"7","key":"535_CR14","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/ja026939x","volume":"125","author":"C Dominguez","year":"2003","unstructured":"Dominguez C, Boelens R, Bonvin AMJJ. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc. 2003;125(7):1731\u20137.","journal-title":"J Am Chem Soc"},{"issue":"2","key":"535_CR15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcf.2013.10.007","volume":"13","author":"G D\u00f6ring","year":"2014","unstructured":"D\u00f6ring G, Bragonzi A, Paroni M, Akt\u00fcrk F-F, Cigana C, Schmidt A, et al. BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros. 2014;13(2):156\u201363.","journal-title":"J Cyst Fibros"},{"issue":"10","key":"535_CR16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/jop.2018.0073","volume":"34","author":"SA Ekanayaka","year":"2018","unstructured":"Ekanayaka SA, McClellan SA, Peng X, Barrett RP, Francis R, Hazlett LD. HMGB1 antagonist, Box A, reduces TLR4, RAGE, and inflammatory cytokines in the cornea of P. aeruginosa-infected mice. J Ocul Pharmacol Ther. 2018;34(10):659\u201369.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"535_CR17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2119\/molmed.2012.00024","volume":"18","author":"M Entezari","year":"2012","unstructured":"Entezari M, Weiss DJ, Sitapara R, Whittaker L, Wargo MJ, Li J, et al. Inhibition of High-Mobility Group Box 1 Protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med. 2012;18(3):477\u201385.","journal-title":"Mol Med"},{"key":"535_CR18","doi-asserted-by":"crossref","unstructured":"Facchini M, De Fino I, Riva C, Bragonzi A. Long term chronic Pseudomonas aeruginosa airway infection in mice. J Vis Exp. 2014;(85).","DOI":"10.3791\/51019"},{"key":"535_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/164913","volume":"2015","author":"S Gangemi","year":"2015","unstructured":"Gangemi S, Casciaro M, Trapani G, Quartuccio S, Navarra M, Pioggia G, et al. Association between HMGB1 and COPD: a systematic review. Mediat Inflamm. 2015;2015:1\u20138.","journal-title":"Mediat Inflamm"},{"issue":"2","key":"535_CR20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1183\/09031936.00029307","volume":"31","author":"A Haegens","year":"2008","unstructured":"Haegens A, Vernooy JHJ, Heeringa P, Mossman BT, Wouters EFM. Myeloperoxidase modulates lung epithelial responses to pro-inflammatory agents. Eur Respir J. 2008;31(2):252\u201360.","journal-title":"Eur Respir J"},{"issue":"6","key":"535_CR21","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.","journal-title":"PLoS Biol"},{"issue":"18","key":"535_CR22","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1021\/jm070365v","volume":"50","author":"M Krajewski","year":"2007","unstructured":"Krajewski M, Rothweiler U, D\u2019Silva L, Majumdar S, Klein C, Holak TA. An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. J Med Chem. 2007;50(18):4382\u20137.","journal-title":"J Med Chem"},{"key":"535_CR23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/978-1-4939-0473-0_58","volume":"1149","author":"I Kukavica-Ibrulj","year":"2014","unstructured":"Kukavica-Ibrulj I, Facchini M, Cigana C, Levesque RC, Bragonzi A. Assessing Pseudomonas aeruginosa virulence and the host response using murine models of acute and chronic lung infection. Methods Mol Biol. 2014;1149:757\u201371.","journal-title":"Methods Mol Biol"},{"issue":"8","key":"535_CR24","doi-asserted-by":"crossref","first-page":"e42748","DOI":"10.1371\/journal.pone.0042748","volume":"7","author":"TG Liou","year":"2012","unstructured":"Liou TG, Adler FR, Keogh RH, Li Y, Jensen JL, Walsh W, et al. Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PLoS ONE. 2012;7(8):e42748.","journal-title":"PLoS ONE"},{"issue":"8","key":"535_CR25","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1073\/pnas.1316925111","volume":"111","author":"B Lu","year":"2014","unstructured":"Lu B, Antoine DJ, Kwan K, Lundb\u00e4ck P, W\u00e4h\u00e4maa H, Schierbeck H, et al. JAK\/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci USA. 2014;111(8):3068\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"535_CR26","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3390\/cancers14092314","volume":"14","author":"R Mezzapelle","year":"2022","unstructured":"Mezzapelle R, Leo M, Caprioglio F, Colley LS, Lamarca A, Sabatino L, et al. CXCR4\/CXCL12 activities in the tumor microenvironment and implications for tumor immunotherapy. Cancers (basel). 2022;14(9):2314.","journal-title":"Cancers (basel)"},{"issue":"4","key":"535_CR27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.chembiol.2007.03.007","volume":"14","author":"L Mollica","year":"2007","unstructured":"Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 2007;14(4):431\u201341.","journal-title":"Chem Biol"},{"key":"535_CR28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijpharm.2019.03.001","volume":"561","author":"I Nazir","year":"2019","unstructured":"Nazir I, Asim MH, Dizdarevi\u0107 A, Bernkop-Schn\u00fcrch A. Self-emulsifying drug delivery systems: impact of stability of hydrophobic ion pairs on drug release. Int J Pharm. 2019;561:197\u2013205.","journal-title":"Int J Pharm"},{"issue":"4","key":"535_CR29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1124\/mol.110.067645","volume":"78","author":"RR Neubig","year":"2010","unstructured":"Neubig RR. Mind your salts: when the inactive constituent isn\u2019t. Mol Pharmacol. 2010;78(4):558\u20139.","journal-title":"Mol Pharmacol"},{"key":"535_CR30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fimmu.2015.00429","volume":"6","author":"L Pawig","year":"2015","unstructured":"Pawig L, Klasen C, Weber C, Bernhagen J, Noels H. Diversity and inter-connections in the CXCR4 chemokine receptor\/ligand family: molecular perspectives. Front Immunol. 2015;6:429.","journal-title":"Front Immunol"},{"issue":"8","key":"535_CR31","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1164\/rccm.200712-1894OC","volume":"178","author":"SM Rowe","year":"2008","unstructured":"Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med. 2008;178(8):822\u201331.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"535_CR32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.20111739","volume":"209","author":"M Schiraldi","year":"2012","unstructured":"Schiraldi M, Raucci A, Mu\u00f1oz LM, Livoti E, Celona B, Venereau E, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med. 2012;209(3):551\u201363.","journal-title":"J Exp Med"},{"key":"535_CR33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2016.03.026","volume":"229","author":"YH Song","year":"2016","unstructured":"Song YH, Shin E, Wang H, Nolan J, Low S, Parsons D, et al. A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system. J Control Release. 2016;229:106\u201319.","journal-title":"J Control Release"},{"issue":"9","key":"535_CR34","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/bioinformatics\/btaa009","volume":"36","author":"G Tomasello","year":"2020","unstructured":"Tomasello G, Armenia I, Molla G. The Protein Imager: a full-featured online molecular viewer interface with server-side HQ-rendering capabilities. Bioinformatics. 2020;36(9):2909\u201311.","journal-title":"Bioinformatics"},{"issue":"4","key":"535_CR35","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jmb.2015.09.014","volume":"428","author":"GCP Van Zundert","year":"2016","unstructured":"Van Zundert GCP, Rodrigues JPGLM, Trellet M, Schmitz C, Kastritis PL, Karaca E, et al. The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes. J Mol Biol. 2016;428(4):720\u20135.","journal-title":"J Mol Biol"},{"issue":"37","key":"535_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.1160755","volume":"1","author":"CT Veldkamp","year":"2008","unstructured":"Veldkamp CT, Seibert C, Peterson FC, De La Cruz NB, Haugner JC, Basnet H, et al. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1\/CXCL12. Sci Signal. 2008;1(37):1\u201310.","journal-title":"Sci Signal"},{"issue":"4","key":"535_CR37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/prot.20449","volume":"59","author":"WF Vranken","year":"2005","unstructured":"Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, Llinas M, et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins Struct Funct Bioinform. 2005;59(4):687\u201396.","journal-title":"Proteins Struct Funct Bioinform"},{"issue":"1","key":"535_CR38","doi-asserted-by":"crossref","first-page":"24826","DOI":"10.1038\/srep24826","volume":"6","author":"CA Waudby","year":"2016","unstructured":"Waudby CA, Ramos A, Cabrita LD, Christodoulou J. Two-dimensional NMR lineshape analysis. Sci Rep. 2016;6(1):24826.","journal-title":"Sci Rep"},{"issue":"4","key":"535_CR39","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1124\/mol.110.066746","volume":"78","author":"P Zhao","year":"2010","unstructured":"Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and \u03b2-Arrestin2 with antinociceptive activity. Mol Pharmacol. 2010;78(4):560\u20138.","journal-title":"Mol Pharmacol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-022-00535-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-022-00535-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-022-00535-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T12:38:57Z","timestamp":1664973537000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-022-00535-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1186\/s10020-022-00535-z","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"8 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies adhered strictly to the Italian Ministry of Health guidelines for the use and care of experimental animals (protocol #733). Research with the <i>P. aeruginosa<\/i> multidrug-resistant (MDR)-RP73 isolate from a CF individual and storage of biological materials were approved by the Ethics Commission of Hannover Medical School, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest. However, M.E.B. is founder and part-owner of HMGBiotech, a company that provides goods and services related to HMGB proteins.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}